[Federal Register Volume 82, Number 47 (Monday, March 13, 2017)]
[Notices]
[Page 13506]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04875]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Siemens 
Healthcare Diagnostics, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.33(a) on or before May 12, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on 
December 14, 2016, Siemens Healthcare Diagnostics, Inc., Attn: RA, 100 
GBC Drive, Mailstop 514, Newark, Delaware 19702 applied to be 
registered as a bulk manufacturer of Ecgonine (9180) a basic class of 
controlled substance listed in schedule II.
    The company plans to produce the listed controlled substance in 
bulk to be used in the manufacture of DEA exempt products.

    Dated: March 6, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-04875 Filed 3-10-17; 8:45 am]
 BILLING CODE 4410-09-P